AP-3 Mediates Tyrosinase but Not TRP-1 Trafficking in Human Melanocytes

Marjan Huizing,* Rangaprasad Sarangarajan,† Erin Strovel,* Yang Zhao,† William A. Gahl,* and Raymond E. Boissy†‡

*Section on Human Biochemical Genetics, Heritable Disorders Branch, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892; and † Department of Dermatology, University of Cincinnati, Cincinnati, Ohio 45267-0592

Submitted October 19, 2000; Revised February 8, 2001; Accepted April 13, 2001 Monitoring Editor: Vivek Malhora

> Patients with Hermansky-Pudlak syndrome type 2 (HPS-2) have mutations in the β 3A subunit of adaptor complex-3 (AP-3) and functional deficiency of this complex. AP-3 serves as a coat protein in the formation of new vesicles, including, apparently, the platelet's dense body and the melanocyte's melanosome. We used HPS-2 melanocytes in culture to determine the role of AP-3 in the trafficking of the melanogenic proteins tyrosinase and tyrosinase-related protein-1 (TRP-1). TRP-1 displayed a typical melanosomal pattern in both normal and HPS-2 melanocytes. In contrast, tyrosinase exhibited a melanosomal (i.e., perinuclear and dendritic) pattern in normal cells but only a perinuclear pattern in the HPS-2 melanocytes. In addition, tyrosinase exhibited a normal pattern of expression in HPS-2 melanocytes transfected with a cDNA encoding the β 3A subunit of the AP-3 complex. This suggests a role for AP-3 in the normal trafficking of tyrosinase to premelanosomes, consistent with the presence of a dileucine recognition signal in the Cterminal portion of the tyrosinase molecule. In the AP-3–deficient cells, tyrosinase was also present in structures resembling late endosomes or multivesicular bodies; these vesicles contained exvaginations devoid of tyrosinase. This suggests that, under normal circumstances, AP-3 may act on multivesicular bodies to form tyrosinase-containing vesicles destined to fuse with premelanosomes. Finally, our studies demonstrate that tyrosinase and TRP-1 use different mechanisms to reach their premelanosomal destination.

INTRODUCTION

Adaptor protein complexes are components of organellar coats having the dual purpose of forming carrier vesicles and recruiting cargo to the newly created vesicles (Schekman and Orci, 1996; Robinson, 1997). Three adaptor complexes (AP-1, AP-2, and AP-3) have been recognized for several years and, recently, AP-4 has been identified (Dell'Angelica *et al.*, 1999a; Hirst *et al.*, 1999). Each of the four known adaptor complexes consists of four different subunits, and each subunit resembles in size and amino acid sequence its counterpart within the other adaptor complexes. One adaptor complex, AP-3, consists of a 160 kDa δ , a 120-kDa β , a 47-kDa μ , and a 22-kDa σ subunit. AP-1 is involved in sculpturing clathrin vesicles from the *trans*-Golgi network, or TGN, whereas AP-2 forms similar vesicles at the plasma membrane (Robinson, 1994). AP-4 appears to be associated with nonclathrin-coated vesicles at or near the TGN (Dell'Angelica *et al.*, 1999a; Hirst *et al.*, 1999). The function of AP-3 remains controversial. It has been suggested that AP-3 functions at the TGN (Simpson *et al.*, 1996; Dell'Angelica *et al.*, 1997a) and also within a late endosome-like compartment (Dell'Angelica *et al.*, 1997a; Simpson *et al.*, 1997). In addition, it has been demonstrated that AP-3 either does not (Simpson *et al.*, 1996; Dell'Angelica *et al.*, 1997b) or does (Dell'Angelica *et al.*, 1998) interact with clathrin.

Whatever role AP-3 plays in generic cells, it appears to exert critical functions in pigment-producing cells. When the ^d subunit of AP-3 is altered in *Drosophila*, the product is the mutant fly *garnet* (Ooi *et al.*, 1997; Simpson *et al.*, 1997), whose ommatidia contain pigment cells with abnormal or absent pigment granules. Similarly, mutations in μ 3, σ 3, and b3A create the *carmine* (Mullins *et al.*, 1999), *orange* (Mullins *et al.*, 1997), and *ruby* (Kretzschmar *et al.*, 2000) eyes, respectively. In the mouse, mutation of δ produces a poorly balanced and hypopigmented animal called *mocha* (Kantheti *et al.*, 1998). When the β 3A subunit of AP-3 is mutated, the resulting mouse, called *pearl*, also lacks normal pigmentation (Feng *et al.*, 1999). Moreover, both *mocha* and *pearl* lack the platelet dense bodies responsible for a normal secondary # Corresponding author. E-mail address: boissyre@ucmail.uc.edu. platelet aggregation response. The combination of a storage

pool deficiency and hypopigmentation places *mocha* and *pearl* among the 14 known murine models (Swank *et al.*, 1998) for a human disorder called Hermansky-Pudlak syndrome, or HPS (Hermansky and Pudlak, 1959; Shotelersuk and Gahl, 1998). This autosomal recessive disease consists of oculocutaneous albinism (Witkop *et al.*, 1990; King *et al.*, 1995; Gahl *et al.*, 1998), a platelet storage pool deficiency due to absent dense bodies (Witkop *et al.*, 1987), and accumulation of a lipid-protein complex called ceroid lipofuscin (Sakuma *et al.*, 1995). In 1996, the gene *HPS-1* was identified as a cause of HPS (Oh *et al.*, 1996) and subsequently demonstrated to be responsible for the melanocyte dysfunction (Boissy *et al.*, 1998), but the disorder is clearly genetically heterogeneous (Hazelwood *et al.*, 1997; Oh *et al.*, 1998). In fact, in 1999 two brothers with documented HPS were reported to express mutations in the β 3A subunit of AP-3 (Dell'Angelica *et al.*, 1999b; Shotelersuk *et al.*, 2000); their disorder is called HPS-2.

These findings suggest that AP-3 functions not only in the formation of or recycling through late endosomes and platelet dense bodies, but also in the pigment-forming process that occurs within the melanosomes of melanocytes. The current dogma of melanogenesis holds that premelanosomes form from the smooth endoplasmic reticulum and later fuse with microvesicles containing tyrosinase, tyrosinase-related protein-1 (TRP-1), pmel17, and other components of the melanogenic pathway (Novikoff *et al.*, 1968; Chakraborty *et al.*, 1989; Zhou *et al.*, 1993). The convergence of the premelanosomes and microvesicles permits the resulting melanosomes to progressively acquire melanin pigment as they mature and travel to melanocytic dendrites for transfer to keratinocytes (King *et al.*, 1995). The microvesicles destined to fuse with premelanosomes are thought to bud from the TGN and possibly recycle through the late endosome (Setaluri, 2000). Because the tyrosinase molecule contains a dileucine-targeting signal motif specific for the μ 3 subunit of AP-3 (Ohno *et al.*, 1998), this enzyme may be cargo transported by an AP-3–mediated mechanism from the TGN/endosome into microvesicles (Höning et al., 1998). It has recently been demonstrated that this dileucine signal within the cytoplasmic tail of human tyrosinase can regulate its targeting to synapse-like microvesicles in a brefeldin A-sensitive AP3-dependent manner when transfected into PC12 cells (Blagoveshchenskaya *et al.*, 1999).

We investigated the role of AP-3 in the process of melanogenesis by examining the localization of tyrosinase and TRP-1 in normal and HPS-2 melanocytes in culture. In normal cells, tyrosinase and TRP-1 colocalize in a granular pattern throughout the entire cell. In HPS-2 melanocytes, tyrosinase is confined to the perinuclear area of the melanocyte within structures resembling multivesicular bodies and/or late endosomes, whereas TRP-1 localization was normal. Transfection of HPS-2 cells with the cDNA encoding the β 3A subunit of AP-3 normalized tyrosinase localization. Therefore, in HPS-2 melanocytes, a striking discordance between the localization of tyrosinase and TRP-1 was found, indicating that these proteins, each critical for melanin production, reach the melanosome by at least two different mechanisms.

MATERIALS AND METHODS

Patients

The patients involved in this study were enrolled in a protocol approved by the National Institute of Child Health and Human Development Institutional Review Board and provided written informed consent. HPS was diagnosed on the basis of oculocutaneous albinism and the absence of platelet dense bodies on electron microscopy. The clinical characteristics of the two patients with HPS-2, i.e., mutations in the β 3A subunit of AP-3, have been previously described (Shotelersuk *et al.*, 2000). In addition, melanocyte cultures developed from patients with oculocutaneous albinism type 1 and type 3, having mutations eliminating the expression of tyrosinase (Zhao and Boissy, 1994) and TRP-1 (Boissy *et al.*, 1996), respectively, were utilized.

Cell Culture

Human melanocytes and fibroblasts were established from normal neonatal foreskins that were obtained from the nursery of Univer-

Figure 1. LAMP-3 and β 3A expression in normal and HPS-2 cells. Fibroblasts (A–D) and melanocytes (E–H) were fixed on coverslips and stained with mouse monoclonal antibodies to LAMP-3 (A, C, E, and G) or rabbit polyclonal antibodies to β 3A (B, D, F, and H). In each normal cell type, the normal distribution patterns of LAMP-3 (green in A and E) and β 3A (red in B and F) are shown. In HPS-2 cells, by comparison, the LAMP-3 pattern was normal (green in C and G) but β 3A immunofluorescence was significantly reduced (red in D and H). Arrows in G and H denote the site of minimal $\beta 3A$ expression in the HPS-2 melanocytes.

Figure 2. Western blots of AP-3 subunits in melanocytes and fibroblasts. Protein extracts (25 mg) of cultured melanocytes and fibroblasts were electrophoresed on a 4–20% polyacrylamide gel, blotted onto nitrocellulose, and treated with antibodies to β 3, μ 3, σ 3, δ 3, and Lamp-1. N-1, N-2, normal cell extract from two different individuals; Pt, HPS-2 cell extract. Expression of β 3, μ 3, $\sigma3$ and $\delta3$ was deficient in HPS-2 fibroblasts and melanocytes; Lamp-1 was normal for the patient and demonstrates a comparable amount of protein loaded in each lane.

sity Hospital (Cincinnati, OH) after routine circumcision and from a 4-mm punch biopsy obtained from the two patients with HPS-2. Skins were incubated in 0.25% trypsin for 2 h at 37°C. The tissue was vortexed for 30 s to separate the dermis from the epidermal cell suspension. The dermis was placed in a 25-cm2 tissue culture flask with growth medium to establish fibroblasts. The growth medium consisted of minimal essential medium (GIBCO-BRL, Grand Island, NY) with 10% fetal bovine serum and 1% antibiotic/antimycotic solution. The epidermal cells were pelleted by centrifugation and resuspended in melanocyte growth medium. Melanocyte growth medium consisted of M154 basal medium (Cascade Biologicals, Portland, OR) supplemented with 4% heat-inactivated fetal bovine serum, 1% antibiotic/antimycotic solution (GIBCO-BRL), $1 \mu g/ml$ transferrin, 1 μ g/ml vitamin E, 5 μ g/ml insulin, 0.6 ng/ml human recombinant basic fibroblast growth factor, 10^{-9} M endothelin-1, and 10^{-8} M α -melanocyte stimulating hormone, from Sigma Chemical (St. Louis, MO) unless indicated differently. All cultures were maintained in a tissue culture incubator at 37° C with 5% CO₂. Growth media were routinely changed twice each week.

Antisera

Mouse monoclonal antiserum to lysosome-associated membrane protein-3 (LAMP-3 or CD-63) and LAMP-1 were obtained from the Developmental Studies Hybridoma Bank (Iowa City, IA), mouse monoclonal antiserum to TRP-1 (or Mel-5) was purchased from Signet Laboratories (Dedham, MA), and mouse monoclonal antiserum to μ 3 (p47A) and σ 3 were obtained from Transduction Laboratories (Lexington, KY). Rabbit polyclonal antiserum to tyrosinase was generously provided by R. King and W.S. Oetting (University of Minnesota, Minneapolis). Antisera to the β 3A and δ 3 subunits of AP-3 and to the γ subunit of AP-1 were obtained from A. Theos and M.S. Robinson (Cambridge Institute for Medical Research, Cambridge, Great Britain).

Immunofluorescence Studies

Human fibroblast or melanocyte monolayers were seeded onto gelatin-coated eight-well Lab-Tek chamber slides (Nunc, Naperville, IL). After 24 h, cells were fixed for 10 min in 2% formaldehyde in phosphate-buffered saline (PBS).

Cells were incubated for 1 h at room temperature in a mixture of mouse monoclonal and rabbit polyclonal antibodies (diluted in PBS, 0.2% saponin [wt/vol], 0.1% bovine serum albumin [wt/vol]). After the incubation, unbound antibodies were removed by washing with PBS three times for 5 min. Cells were then incubated for 30 min with a mixture of secondary antibodies: Cy-2–conjugated donkey antimouse and Cy-3–conjugated donkey anti-rabbit (Jackson Immunoresearch, West Grove, PA). After washing the cells three times for 5 min in PBS, the cells were mounted onto glass slides with Fluoromont G (Southern Biotechnologies, Birmingham, AL).

Microscopy was performed on an Axioscop-20 or an LSM 510 upright confocal microscope (Zeiss, Oberkochen, Germany). In the latter case, the fluorochromes were excited with appropriate wavelength argon laser light. Emitted light was filtered with a 505-nm pass filter. The pixel dimensions were 0.17×0.17 mm, and the optical section thickness was $3.8 \mu m$.

Western Blotting

Proteins in the cell extracts were separated by SDS-PAGE, with the use of 4–20% gradient precast gels (Novex, San Diego, CA), and electroblotted onto 0.2- μ m nitrocellulose membranes (Schleicher & Schuell, Keene, NH). Nonspecific sites on the membrane were blocked by incubation in 5% (wt/vol) nonfat dry milk in PBS, 0.1% Tween. The membranes were incubated with primary antiserum diluted in PBS containing 0.1% Tween, followed by incubation with horseradish peroxidase-conjugated secondary antibodies (Amersham Pharmacia Biotech, Piscataway, NJ). Detection was performed with the enhanced chemiluminescence (ECL) system, according to the manufacturer's instructions (Amersham Pharmacia Biotech).

Electron Microscopy

Melanocytes were seeded onto gelatin-coated eight-well Lab-Tek chamber slides. After 24 h, cells were fixed in wells with halfstrength Karnovsky's fixative (Karnovsky, 1965) in 0.2 M sodium cacodylate buffer at pH 7.2 for 30 min at room temperature. The cells were washed three times in buffer and in some cases incubated in a 0.1% solution of dihydroxyphenylalanine (L-DOPA) for 2 h twice at 37°C for the histochemical identification of tyrosinase. Cells were then postfixed with 1% osmium tetroxide containing 1.5% potas-

sium ferrocyanide (Karnovsky, 1971) for 30 min. The cells were washed, stained *en bloc* with 0.5% uranyl acetate for 30 min, dehydrated, and embedded in Eponate 12. Cells were sectioned on an RMC, Inc. (Tucson, AZ) MT 6000-XL ultramicrotome, stained with aqueous solutions of uranyl acetate (2%) and lead citrate (0.3%) for 15 min each, and then viewed and photographed in a JEM-100CX transmission electron microscope (JEOL, Tokyo, Japan). All tissue processing supplies were purchased from Ted Pella, Inc. (Tustin, CA).

Immunocytochemistry/Electron Microscopy

Melanocytes were seeded onto gelatin-coated eight-well Lab-Tek chamber slides as described above. After 24 h, cells were washed in PBS for 5 min and then fixed in cold one-quarter-strength Karnovsky's fixative at 4°C for 5 min. Cells were then treated with 0.1% glycine in PBS for 5 min, permeablized with 0.02% Triton X-100 (in distilled water) for 1 min, and incubated for 30 min in 5% dry milk/1% bovine serum albumin A in distilled water. Cells were incubated in nonimmune blocking serum from the Vectastain ABC kit (Vector Laboratories, Burlingame, CA) for 30 min and then in Mel-5 (1:100) at room temperature for 1 h. Cells were processed with the Vectastain Elite ABC kit according to the manufacturer's instructions; the diaminobenzidine tetrahydrochloride incubation period lasted 10 min. Cells were then processed for electron microscopy as described above except that sections were stained with Reynold's alkaline lead only.

Transfection of HPS-2 Melanocytes

The complete cDNA encoding the β 3A subunit of the human AP-3 complex was inserted into the *EcoRV/XhoI* site in pcDNA3.1(+) expression vector (Invitrogen, Carlsbad, CA). After confirmation of the presence of insert by restriction digest and sequencing, the plasmid was utilized for transfection into cultures of HPS-2 melanocytes. Briefly, confluent cultures of melanocytes were transfected with either vector alone (pcDNA3.1[+]) or the β 3A subunit-containing construct (pcDNA[β 3A]) with the use of Effectene reagent according to the manufacturer's protocols with modifications (Qiagen, Valencia, CA). The $pcDNA(+)$ and $pcDNA(\beta 3A)$ were incubated with the appropriate reagents from the Effectene transfection kit and added to the melanocyte cultures. Selection with G418 (0.5 mg/ml) was started 72 h after initial incubation. After 3 d of selection, the medium was changed and cells allowed to recover for 2 d. The melanocyte cultures were maintained in growth medium without G418 for 5 d. To confirm successful transfection and protein expression, an aliquot of cells was used for immunohistochemical analysis.

RESULTS

In humans, deficiency of the β 3A subunit of AP-3 has been demonstrated only in cultured fibroblasts (Dell'Angelica *et al.*, 1999b). Yet, the phenotypic expression of the clinical disorder, HPS-2, involves dysfunction of platelets and melanocytes (Shotelersuk *et al.*, 2000). Consequently, we investigated whether melanocytes also exhibit a deficiency of b3A. As previously demonstrated (Dell'Angelica *et al.*, 1999b), immunofluorescence studies of normal fibroblasts revealed a typical lysosomal distribution for both LAMP-3 and the β 3A subunit of AP-3 (Figure 1, top). Normal melanocytes also displayed a fluorescent signal for the LAMP-3 and β 3A antibodies (Figure 1, middle and bottom). However, although HPS-2 fibroblasts and cultured melanocytes exhibited a normal amount and pattern of LAMP-3 expression, each of these cell types manifested a marked deficiency of β 3A expression (Figure 1).

In fibroblasts, deficiency of β 3A was accompanied by deficiency of the other three AP-3 subunits, presumably because the AP-3 complex fails to form and stabilize its components (Dell'Angelica *et al.*, 1999b). We now demonstrate that Western blots also showed markedly reduced levels of the other AP-3 subunits in cultured melanocytes from an HPS-2 patient that were compared with normal (Figure 2).

These experiments confirm that HPS-2 melanocytes in culture express the β 3A subunit deficiency, as expected, and can be used to study the effects of the absence of AP-3 upon protein trafficking. Subsequent investigations focused on two pivotal enzymes in melanogenesis, i.e., tyrosinase and TRP-1. These proteins are targeted to melanosomes and, indeed, tyrosinase and TRP-1 trafficked to the melanosomes in normal melanocytes. However, the relative amounts of tyrosinase/TRP-1 expression per melanocyte are not always equal, as illustrated by the immunofluorescence studies (Fig-

Figure 3. TRP-1 and tyrosinase distribution in normal and HPS-2 melanocytes. Melanocyte monolayers were fixed in 2% formaldehyde and stained with anti–TRP-1 monoclonal (green) and antityrosinase polyclonal (red) antibodies. In normal melanocytes (A– C), TRP-1 (A) and tyrosinase (B) exhibited a similar distribution throughout the melanocyte $(C =$ merged image). In HPS-2 cells (D–F), TRP-1 (D) had a normal distribution, but tyrosinase (E) was localized mainly in the perinuclear area and was markedly absent from the cell periphery (arrowheads) $(F =$ merged image).

Figure 4. TRP-1 is present within the melanosomes of HPS-2 melanocytes. Cultured HPS-2 (A), OCA-1 (B), and OCA-3 (C) melanocytes, containing predominantly hypomelanized melanosomes, were processed for the immunocytochemical localization of TRP-1 with the use (top row) or omission (bottom) of the MEL-5 primary antibody. Peroxidase reaction product occurred in melanosomes (arrows) of the HPS-2 melanocytes (A), null for β 3A, and the OCA-1 melanocytes (B), null for tyrosinase. In contrast, peroxidase reaction product did not occur in melanosomes (arrowheads) of the OCA-3 melanocytes (C), null for TRP-1 and all melanocyte types not processed with Mel 5 primary antibody (bottom). Bar, $0.5 \mu m$.

ure 3, left column). In HPS-2 melanocytes, TRP-1 displayed a normal, melanosomal distribution, with fluorescence appearing throughout the dendrites as well as in the perinuclear region (Figure 3, top, right). Normal localization of TRP-1 to the melanosomes in HPS-2 melanocytes was confirmed by immunocytochemical findings at the ultrastructural level (Figure 4). Tyrosinase, however, appeared mainly around the nucleus and was markedly absent from the cell periphery. Double-exposure fluorescence studies revealed the lack of colocalization of tyrosinase and TRP-1 in the HPS-2 melanocytes' dendrites, indicating that the absence of functional AP-3 prevented tyrosinase from entering and traveling with melanosomes.

To further assess the distribution pattern of tyrosinase in HPS-2 melanocytes, we used DOPA histochemistry at the ultrastructural level. Tyrosinase activity was markedly reduced in most of the melanosomes throughout the cell body and dendrites of HPS-2 melanocytes (Figure 5). Approximately, 40–80% of the melanosomes within the dendrites of a melanocyte lacked tyrosinase and morphologically resembled stage I melanosomes. These organelles contained much floccular material and melanofilament-like structures. However, mature functional tyrosinase, as revealed by DOPA histochemistry, was normally trafficked through and exited from the Golgi apparatus (Figure 6). Reaction product in the *trans*-most cisternae and coated vesicles of the TGN appeared normal in HPS-2 melanocytes. Predominant in the AP-3–deficient HPS-2 melanocyte was the prevalence of multivesiculated bodies/late endosome-like structures that contained tyrosinase in unusual aggregates (Figure 7). These abundant structures contained multiple exvaginations of the limiting membrane lacking reaction product/tyrosinase.

HPS-2 melanocytes were subsequently transfected with a cDNA encoding the β 3A subunit of AP-3 (Figure 8). Tyrosinase localization in HPS-2 melanocytes transfected with mock cDNA remained restricted to the perinuclear area

(Figure 8C). In contrast, tyrosinase acquired normal localization throughout the cell body and dendrites of HPS-2 melanocytes successfully transfected with the β 3A (Figure 8D). In addition, the expression of the δ subunit of AP-3 was up-regulated in HPS-2 melanocytes transfected with β 3A (Figure 8, E and F).

DISCUSSION

Adaptor protein complexes function to create new vesicles from extant membranes and to select cargo proteins that will be constituents of the newly formed vesicles. AP-3 was originally considered to serve this function at the TGN and to target proteins to the late endosome or lysosome (Simpson *et al.*, 1996, 1997; Dell'Angelica *et al.*, 1997a). However, AP-3 may also be localized to a more distal compartment, perhaps the late endosome (Dell'Angelica *et al.*, 1997a; Simpson *et al.*, 1997; Faundez and Kelly, 2000). In yeast, deficiency of any of the AP-3 subunits causes failure of alkaline phosphatase and Vam3p, a t-SNARE, to reach the vacuole (Cowles *et al.*, 1997; Darsow *et al.*, 1998). In mice, mutations in the b3A subunit of AP-3 produce the *pearl* mouse, with hypopigmentation and platelet storage pool deficiency (Feng *et al.*, 1999; Zhen *et al.*, 1999). The human correlate of pearl occurs in patients with HPS-2, a disorder manifest in two brothers having mild oculocutaneous albinism, absent platelet dense bodies, and neutropenia (Dell'Angelica *et al.*, 1999b; Shotelersuk *et al.*, 2000). These individuals have compound heterozygous mutations in the β 3A subunit of AP-3, resulting in a 21-amino acid deletion (D390-410) and an amino acid substitution (L580R). Fibroblasts cultured from these patients have a reduction in all four AP-3 subunits and exhibit enhanced internalization of the lysosomal integral membrane proteins CD63, LAMP-1, and LAMP-2 at the plasma membrane (LeBorgne *et al.*, 1998; Dell'Angelica *et al.*,

Figure 5. HPS-2 versus control melanocytes contain many melanosomes devoid of tyrosinase. Cultured HPS-2 (A) and control (B) melanocytes were processed for DOPA histochemistry to localize catalytically functional tyrosinase. Many of the melanosomes in the HPS-2 melanocytes remained amelanotic (arrowheads), indicating that they lacked tyrosinase, whereas those in the control melanocytes were heavily pigmented. However, in the HPS-2 melanocytes, reaction product and thus tyrosinase was apparent in some melanosomes (arrows) and in an occasional larger multivesiculated body/late endosome-like vesicles (open arrows). Bar, $2.0 \mu m$.

1999b), indicating a role for AP-3 in the normal trafficking of these proteins. Nevertheless, the ultimate steady-state levels and distribution of an integral lysosomal membrane protein

such as CD63 (LAMP-3) appears normal in AP-3–deficient cells (Figure 1), either because default trafficking by the plasma membrane (Dell'Angelica *et al.*, 1999b) has delivered

Figure 6. HPS-2 melanocytes exhibit a normal tyrosinase profile in the TGN. Cultured control (A) and HPS-2 (B) melanocytes were processed for DOPA histochemistry. In both cell types, reaction product was similarly present in the *trans*-most cisternae of the Golgi apparatus (arrows) and in coated vesicles budding off (arrowheads) and free in the vicinity of the TGN. Bar, $0.5 \mu m$.

a normal contingent of LAMP-3 to the lysosomal membrane or because residual AP-3 has carried sufficient LAMP-3 to the lysosome.

Although AP-3–deficient fibroblasts express an abnormal phenotype in vitro, more striking in vivo manifestations of β 3A subunit deficiency are caused by abnormal pigment production by melanocytes. This process depends on a series of melanogenetic enzymes whose trafficking to the melanosome can be assessed in melanocytes cultured from HPS-2 patients. Indeed, HPS-2 melanocytes, like fibroblasts, do exhibit a deficiency of the β 3A subunit of AP-3 (Figures 1 and 8). Moreover, the μ , σ , and δ subunits of AP-3 are markedly deficient in HPS-2 melanocytes (Figures 2 and 8), presumably because they are not stabilized in a complete $AP-3$ complex because of absence of the β 3A subunit.

The μ 3 subunit of AP-3 is recognized to interact with cargo proteins by virtue of a dileucine motif in the cytoplasmic tail of such proteins. Tyrosinase has an appropriate dileucine motif, and studies with the use of yeast 2-hybrids (Dell'Angelica *et al.*, 1997a) and surface plasmon resonance (Höning *et al.*, 1998) have demonstrated that μ 3A and tyrosinase interact with each other. However, it is not the dileucine residue alone that determines which proteins are recognized by the μ subunit of AP-3. In LIMP II, for example, the acidic amino acid residues Asp470 and Glu471, located four and five residues proximal to the dileucine motif, are critical for binding to AP-3 (Höning *et al.*, 1998; Tabuchi *et al.*, 2000), as well as for targeting to lysosomes (Pond *et al.*, 1995). Tyrosinase and LIMP II share the same D(E)ERXP amino acid sequence preceding the dileucine signal, and the two acidic amino acids in this motif appear essential for binding to AP-3. Moreover, mutagenesis of two leucine residues within the dileucine-signaling motif of tyrosinase has been shown to prevent late endosomal localization in HeLa cells transfected with the construct (Calvo *et al.*, 1999). Binding to AP-3 specifically has been abrogated in nature on at least two occasions. First, when the cytoplasmic tail is truncated at residue -10 in the murine *platinum* allele of tyrosinase, the dileucine motif is lost, tyrosinase is

misrouted, and oculocutaneous albinism results (Beerman *et* al., 1995). Second, when β 3A mutations result in deficiency of μ 3 in humans with HPS-2, tyrosinase is misrouted in melanocytes (Figures 3 and 7), and an oculocutaneous albinism typical of HPS results (Dell'Angelica *et al.*, 1999b; Shotelersuk *et al.*, 2000). This misrouting of tyrosinase can be rescued with transfection of the β 3A subunit (Figure 8).

The amino acid sequence of TRP-1 surrounding its dileucine signal differs from that of tyrosinase. Instead of having two acidic amino acids in the -5 and -4 positions relative to the dileucines, TRP-1 has a single acidic residue. This may account for the failure of AP-3 deficiency to disturb the normal distribution of TRP-1 in HPS-2 melanocytes (Figures 3 and 8), in marked contrast to the effects on tyrosinase. In fact, Höning et al. (1998) demonstrated that, when the -5 amino acid of LIMP II is substituted by an A, as occurs naturally in TRP-1, interaction with AP-3 is abrogated.

These studies of normal and HPS-2 melanocytes offer a fuller understanding of the movement of melanogenic proteins within these cells. Tyrosinase appears to move from the TGN to premelanosomes by a vesicle-mediated path (Maul, 1969; Chakraborty *et al.*, 1989). Coated vesicles containing tyrosinase have been shown to form at the *trans*-most cisternea of the Golgi, and 50-nm vesicles containing tyrosinase eventually fuse with stage 1 premelanosomes. It remains unknown whether this route of translocation between the TGN and the premelanosome is direct or requires an intervening structure, such as the late endosome or multivesicular sorting body (Setaluri, 2000). The intervening structures through which tyrosinase could transit may also represent the recently described hybrid organelles (Luzio *et al.*, 2000). Lysosomes can fuse directly with late endosomes forming a hybrid organelle from which lysosomes are then reformed by a process involving condensation of contents (Bright *et al.*, 1997; Mullock *et al.*, 1998). Structures morphologically resembling late endosome/multivesicular bodies, particularly those containing reaction product after DOPA histochemistry, are relatively rare in normal melanocytes (Figure

control (A) and HPS-2 (B and C) melanocytes were processed for DOPA histochemistry. (A) Multivesicular bodies with minimal (1) or no (2) reaction product were occasionally present in control melanocytes. (B) In contrast, multivesicular bodies with much reaction product (arrows) were abundant in HPS-2 melanocytes. (C) The HPS-2 multivesiculated bodies exhibited finger-like protrusions of their limiting membranes (1) and the DOPA positive reaction product appeared as aggregates (2), and/or within vesicles (3). Bars: A and B, 0.4 μ m; C, 0.25 μ m.

7). This suggests that, if tyrosinase is shuttled through an intervening structure, this transit occurs rapidly.

In the β 3A-deficient HPS-2 melanocytes, tyrosinase was present in the *trans*-most cisternea of the Golgi as well as in nearby coated vesicles (Figure 6), indicating that a coat protein complex other than AP-3 functions in the formation of cargo vesicles at this site in the melanocyte. This is consistent with localization studies in normal melanocytes (Figure 1), which demonstrated a distribution pattern of AP-3 extending beyond the immediate perinuclear/Golgi area.

In contrast to its normal appearance in the TGN and coated vesicles of HPS-2 melanocytes, tyrosinase apparently does not efficiently reach premelanosomes (Figures 5 and 7). Instead, structures resembling late endosomes/multivesicular bodies are prevalent and contain abundant DOPA reaction product, i.e., tyrosinase. However, the structures also contain exvaginations lacking tyrosinase. In the absence of a functional AP-3 complex, these exvaginations may represent vesicles aborted or delayed in their formation and lacking both tyrosinase cargo and clathrin. Consequently, they would be unable to form a budding transport vesicle destined for the premelanosome. The exact role of AP-3 in this putative process has not been determined and requires further investigation.

However, some tyrosinase successfully reaches the melanosome, as demonstrated by the few melanized melanosomes present in HPS melanocytes. This could result from the inadvertent fusion and incorporation of Golgi-derived vesicles containing tyrosinase with premelanosomes in the vicinity. It is also possible that this results from an alternate

Figure 8. Tyrosinase localization on HPS-2 melanocytes transfected with the cDNA encoding the β subunit of AP-3. Cultured HPS-2 melanocytes were transfected with vector alone (A, C, and E) or the cDNA encoding the β subunit of AP-3 (B, D, and F). Selected transfectants were immunocytochemically processed for colocalization of the β 3A subunit of AP-3 (red) and TRP-1 (green) (A and B); colocalization of the γ subunit of AP-1 (green) and tyrosinase (red) (C and D); and localization of the δ subunit of AP-3 (red) (E and F); G shows normal human melanocytes immunocytochemically processed for the localization of tyrosinase (red). Both the β 3A (arrowheads in B) and the δ subunits of AP-3 (arrowheads in F) were up-regulated after transfection of the β 3A subunit of AP-3. Concomitantly, expression of tyrosinase was normalized throughout the dendrites in the HPS-2 cells transfection with the β 3A subunit of AP-3 (arrowheads in D) resembling tyrosinase expression in normal human melanocytes (G). Expression of both TRP-1 (green in A vs. B) and the γ subunit of AP-1 (green in C vs. D) were unaffected by transfection.

pathway for trafficking tyrosinase that is not AP-3 dependent. This could parallel the situation of the trafficking of synaptic vesicle proteins, which can apparently arrive into the synaptic vesicle via the plasma membrane (AP-2–mediated, brefeldin A-insensitive route) or the endosome (AP-3 mediated, brefeldin A-sensitive route) (Blagoveshchenskaya and Cutler, 2000). Similarly, it has been demonstrated that lysosomal enzyme transport from the Golgi to the lysosome can occur via the cell surface (Braun *et al.*, 1989). This is conceivable in light of the fact that melanosomes and lysosomes appear to have a common lineage (Orlow, 1995). An alternative route of tyrosinase trafficking would also be consistent with observations made in melanocytes from HPS1 (Boissy *et al.*, 1998) and Chediak-Higashi syndrome (Zhao *et al.*, 1994), in which some tyrosinase reaches the melanosome

whereas most is targeted away from the melanosome or secreted from the melanocyte, respectively.

We conclude that the AP-3 complex mediates tyrosinase trafficking in human melanocytes, that the location of this process is distal to the TGN and coated vesicle formation, and that TRP-1 reaches the premelanosome by a process not requiring functional AP-3. We speculate that AP-3 acts on late endosomes or multivesicular bodies to form tyrosinasecontaining vesicles which subsequently fuse with premelanosomes in the melanogenic pathway.

ACKNOWLEDGMENTS

This work was supported in part by Grant AR-45429 fro the National Institutes of Health (to R.E.B.).

REFERENCES

Beerman, F., Orlow, S.J., Boissy, R.E., Schmidt, A., Boissy, Y.L., and Lamoreux, M.L. (1995). Misrouting of tyrosinase with a truncated cytoplasmic tail as a result of the murine platinum c^p mutation. Exp. Eye Res. *61*, 599–607.

Blagoveshchenskaya, A.D., and Cutler, D.F. (2000). Sorting to synaptic-like microvesicles from early, and late endosomes requires overlapping but not identical targeting signals. Mol. Biol. Cell *11*, 1801–1814.

Blagoveshchenskaya, A.D., Hewitt, E.W., and Cutler, D.F. (1999). Di-leucine signals mediate targeting of tyrosinase and synaptotagmin to synaptic-like microvesicles with PC12 cells. Mol. Biol. Cell *10*, 3979–3990.

Boissy, R.E., Zhao, H., Oetting, W.S., Austin, L.M., Wildenberg, S.C., Boissy, Y.L., Zhao, Y., Sturm, R.A., Hearing, V.J., King, R.A., and Nordlund, J.J. (1996). Mutation in and lack of expression of tyrosinase related protein-1 (TRP-1) in melanocytes from an individual with brown oculocutaneous albinism: a new subtype of albinism classified as OCA3. Am. J. Hum. Genet. *58*, 1145–1156.

Boissy, R.E., Zhao, Y., and Gahl, W.A. (1998). Altered protein localization in melanocytes from Hermansky-Pudlak syndrome: support for the role of the *HPS* gene product in intracellular trafficking. Lab. Invest. *78*, 1037–1048.

Braun, M., Wahead, A., and von Figura, K. (1989). Lysosomal acid phosphatase is transported to lysosomes via the cell surface. EMBO J. *8*, 3633–3640.

Bright, N.A., Reaves, B.J., Mullock, B.N., and Luzio, J.P. (1997). Dense core lysosomes can fuse with late endosomes and are reformed from the resultant hybrid organelles. J. Cell Sci. *110*, 2027– 2040.

Calvo, P.A., Frank, D.W., Bieler, B.M., Berson, J.F., and Marks, M.S. (1999). A cytoplasmic sequence in human tyrosinase defines a second class of di-leucine-based sorting signals for late endosomal and lysosomal delivery. J. Biol. Chem. *274*, 12780–12789.

Chakraborty, A.K., Mishima, Y., Inazu, M., Hatta, S., and Ichihashi, M. (1989). Melanogenic regulatory factors in coated vesicles from melanoma cells. J. Invest. Dermatol. *93*, 616–620.

Cowles, C.R., Odorizzi, G., Payne, G.S., and Emr, S.D. (1997). The AP-3 adaptor complex is essential for cargo-selective transport to the yeast vacuole. Cell *91*, 109–118.

Darsow, T., Burd, C.G., and Emr, S.C. (1998). Acidic di-leucine motif essential for AP-3-dependent sorting and restriction of the functional specificity of the Vam3p vacuolar tSNARE. J. Cell Biol. *142*, 913–922.

Dell'Angelica, E.C., Klumperman, J., Stoorvogel, W., and Bonifacino, J.S. (1998). Association of the AP-3 adaptor complex with clathrin. Science *280*, 431–434.

Dell'Angelica, E.C., Mullins, C., and Bonifacino, J.S. (1999a). AP-4, a novel protein complex related to clathrin adaptors. J. Biol. Chem. *274*, 7278–7285.

Dell'Angelica, E.C., Ohno, H., Ooi, C.E., Rabinovich, E., and Roche, K.W. (1997a). AP-3: an adaptor-like protein complex with ubiquitous expression. EMBO J. *16*, 917–928.

Dell'Angelica, E.C., Ooi, C.E., and Bonifacino, J.S. (1997b). β3Aadaptin, a subunit of the adaptor-like complex AP-3. J. Biol. Chem. *272*, 15078–15084.

Dell'Angelica, E.C., Shotelersuk, V., Aguilar, R.C., Gahl, W.A., and Bonifacino, J.S. (1999b). Altered trafficking of lysosomal proteins in Hermansky-Pudlak syndrome due to mutations in the β 3A subunit of the AP-3 adaptor. Mol. Cell *3*, 11–21.

Faundez, V.V., and Kelly, R.B. (2000). The AP-3 complex required for endosomal synaptic vesicle biogenesis is associated with a casein kinase Ia-like isoform. Mol. Biol. Cell *10*, 2591–2604.

Feng, L., Seymour, A.B., Jiang, S., To, A., Peden, A.A., Novak, E.K., Zhen, L., Rusiniak, M.E., Eicher, E.M., Robinson, M.S., Gorin, M.B., and Swank, R.T. (1999). The b3A subunit gene (*Ap3b1*) of the AP-3 adaptor complex is altered in the mouse hypopigmentation mutant pearl, a model for Hermansky Pudlak syndrome and night blindness. Hum. Mol. Genet. *8*, 323–330.

Gahl, W.A., Brantly, M., Kaiser-Kupfer, M.I., Iwata, F., Hazelwood, S., Shotelersuk, V., Duffy, L.F., Kuehl, E.M., Troendle, I., and Bernardini, I. (1998). Genetic defects and clinical characteristics of patients with a form of oculocutaneous albinism (Hermansky-Pudlak syndrome). N. Engl. J. Med. *338*, 1258–1264.

Hazelwood, S., Shotelesuk, V., Wildenberg, S.C., Chen, D., Iwata, F., Kaiser-Kupfer, M.I., White, J.G., King, R.A., and Gahl, W.A. (1997). Evidence for locus heterogeneity in Puerto Ricans with Hermansky-Pudlak syndrome. Am. J. Hum. Genet. *61*, 1088–1094.

Hermansky, F., and Pudlak, P. (1959). Albinism associated with hemorrhagic diathesis and unusual pigmented reticular cells in the bone marrow: report of two cases with histochemical studies. Blood *14*, 162–169.

Hirst, J., Bright, N.A., Rous, B., and Robinson, M.S. (1999). Characterization of a fourth adaptor-related protein complex. Mol. Biol. Cell *10*, 2787–2802.

Höning, S., Sandoval, I.V., and von Figura, K. (1998). A di-leucinebased motif in the cytoplasmic tail of LIMP-II and tyrosinase mediates selective binding of AP-3. EMBO J. *17*, 1304–1314.

Kantheti, P., Qiao, X., Diaz, M., Peden, A.A., Meyer, G.E., Carskadon, S.L., Kapfhamer, D., Sufalko, D., Robinson, M.S., Noebels, J.L., and Burmeister, M. (1998). Mutation in AP-3 δ in the mocha mouse links endosomal transport to storage deficiency in platelets, melanosomes, and synaptic vesicles. Neuron *21*, 111–122.

Karnovsky, M.J. (1965). A formaldehyde-glutaraldehyde fixative of high osmolality for use in electron microscopy. J. Cell Biol. *27*, 137 (Abstract).

Karnovsky, M.J. (1971). Use of ferrocyanide-reduced oximum tetroxide in electron microscopy. J. Cell Biol. *51*, 146 (Abstract).

King, R.A., Hearing, V.J., Creel, D.J., and Oetting, W.S. (1995). Albinism. In: The Metabolic and Molecular Bases of Inherited Disease, 7th ed, eds. C.R. Scriver, A.L. Beaudet, W.S. Sly, and D.V. Valle, New York: McGraw-Hill, 4353–4392.

Kretzschmar, D., Poeck, B., Roth, H., Ernst, R., Keller, A., Porsch, M., Stauss, R., and Pflugfelder, G.O. (2000). Defective pigment granule biogenesis, and aberrant behavior caused by mutations in the *Drosophila* AP-3 beta adaptin gene *ruby*. Genetics *155*, 213–223.

LeBorgne, R., Alconada, A., Bauer, U., and Hoflack, B. (1998). The mammalian AP-3 adaptor-like complex mediates the intracellular transport of lysosomal membrane glycoproteins. J. Biol. Chem. *273*, 29451–29461.

Luzio, J.P., Rous, B.A., Bright, N.A., Pryer, P.R., Mullock, B.M., and Piper, R.C. (2000). Lysosome-endosome fusion, and lysosome biogenesis. J. Cell Sci. *113*, 1515–1524.

Maul, G.G. (1969). Golgi-melanosome relationship in human melanoma in vitro. J. Ultrastruct. Res. *26*, 163–176.

Mullins, C., Hartnell, L.M., Wassarman, D.A., and Bonifacino, J.S. (1997). Mutations in subunits of the AP-3 adaptor complex result in defective pigment granule biogenesis in *Drosophila melanogaster*. Mol. Biol. Cell *10*, 223 (Abstract).

Mullins, C., Hartnell, L.M., Wassarman, D.A., and Bonifacino, J.S. (1999). Defective expression of the μ 3 subunit of the AP-3 adaptor complex in the *Drosophila* pigmentation mutant carmine. Mol. Gen. Genet. *262*, 401–412.

Mullock, B.M., Bright, N.A., Fearon, C.W., Gray, S.R., and Luzio, J.P. (1998). Fusion of lysosomes with late endosomes produces a hybrid organelle of intermediate density and is NSF dependent. J. Cell Biol. *140*, 591–601.

Novikoff, A., Albala, A., and Biempica, L. (1968). Ultrastructural and cytochemical observations on B16 and Harding-Passey melanomas: the origin of premelanosomes and compound melanosomes. J. Histochem. Cytochem. *16*, 299–319.

Oh, J., Bailin, T., Fukai, K., Feng, G.H., Ho, L., Mao, J., Frenk, E., Tamura, N., and Spritz, R.A. (1996). Positional cloning of a gene for Hermansky-Pudlak syndrome, a disorder of cytoplasmic organelles. Nat. Genet. *14*, 300–306.

Oh, J., Ho, L., Ala-Mello, S., Amato, D., Armstrong, L., Bellucci, S., Carakushansky, G., Ellis, J.P., Fong, C.T., Green, J.S., Heon, E., Legius, E., Levin, A.V., Nieuwenhius, H.K., Pinckers, A., Tamura, N., Whiteford, M.L., Yamasaki, H., and Spritz, R.A. (1998). Mutation analysis of patients with Hermansky-Pudlak syndrome: a frameshift hot spot in the HPS gene and apparent locus heterogeneity. Am. J. Hum. Genet. *62*, 593–598.

Ohno, H., Aguilar, R.C., Yeh, D., Taura, D., Saito, T., and Bonifacino, J.S. (1998). The medium subunits of adaptor complexes recognize distinct but overlapping sets of tyrosine-based sorting signals. J. Biol. Chem. *273*, 25915–25921.

Ooi, C.E., Moreira, J.E., Dell'Angelica, E.C., Poy, G., Wassarman, D.A., and Bonifacino, J.S. (1997). Altered expression of a novel adaptin leads to defective pigment granule biogenesis in the *Drosophila* eye color mutant garnet. EMBO J. *16*, 4508–4518.

Orlow, S.J. (1995). Melanosomes are specialized members of the lysosomal lineage of organelles. J. Invest. Dermatol. *105*, 3–7.

Pond, L., Kuhn, L.A., Teyton, L., Schutze, M.P., Tainer, J.A., Jackson, M.R., and Peterson, P.A. (1995). A role for acidic residues in dileucine motif-based targeting to the endocytic pathway. J. Biol. Chem. *270*, 19989–19997.

Robinson, M.S. (1994). The role of clathrin, adaptors and dynamin in endocytosis. Curr. Opin. Cell Biol. *6*, 538–544.

Robinson, M.S. (1997). Coats and vesicle budding. Trends Cell Biol. *7*, 99.

Sakuma, T., Monma, M., Satodate, R., Satoh, T., Takeda, R., and Kuriya, S. (1995). Ceroid pigment deposition in circulating blood monocytes and T lymphocytes in Hermansky-Pudlak syndrome: an ultrastructural study. Pathol. Int. *45*, 866–870.

Schekman, R., and Orci, L. (1996). Coat proteins and vesicle budding. Science *271*, 1526–1539.

2084 Molecular Biology of the Cell

Setaluri, V. (2000). Sorting, and targeting of melanosomal membrane proteins: signals, pathways and mechanisms. Pigment Cell Res. *13*, 128–134.

Shotelersuk, V., Dell'Angelica, E.C., Hartnell, L., Bonifacino, J.S., and Gahl, W.A. (2000). A new variant of Hermansky-Pudlak syndrome due to mutations in a gene responsible for vesicle formation. Am. J. Med. *108*, 423–427.

Shotelersuk, V., and Gahl, W.A. (1998). Hermansky-Pudlak syndrome: models for intracellular vesicle formation. Mol. Genet. Metab. *65*, 85–96.

Simpson, F., Bright, N.A., West, M.A., Newman, L.S., Darnell, R.B., and Robinson, M.S. (1996). A novel adaptor-related protein complex. J. Cell Biol. *133*, 749–760.

Simpson, F., Peden, A.A., Christopoulou, L., and Robinson, M.S. (1997). Characterization of the adaptor-related protein complex, AP-3. J. Cell Biol. *137*, 835–845.

Swank, R.T., Novak, E.K., McGarry, M.P., Rusiniak, M.E., and Feng, L. (1998). Mouse models of Hermansky-Pudlak syndrome: a review. Pigment Cell Res. *11*, 60–80.

Tabuchi, N., Akasaki, K., and Tsuji, H. (2000). Two acidic amino acid residues, asp(470), and glu(471), contained in the carboxyl cytoplasmic tail of a major lysosomal membrane protein, LGP85/LIMP II, are important for its accumulation in secondary lysosomes. Biochem. Biophys. Res. Commun. *270*, 557–563.

Witkop, C.J.J., Krumwiede, M., Sedano, H., and White, J.G. (1987). Reliability of absent platelet dense bodies as a diagnostic criterion for Hermansky-Pudlak syndrome. Am. J. Hematol. *26*, 305–311.

Witkop, C.J.J., Nunez-Babcock, M., Rao, G.H., Gaudier, F., Summers, C.G., Shanahan, F., Harmon, K.R., Townsend, D., Sedano, H.O., and King, R.A. (1990). Albinism and Hermansky Pudlak syndrome in Puerto Rico. Bol. Asoc. Med. P.R. *82*, 333–339.

Zhao, H., and Boissy, R.E. (1994). Distinguishing between the catalytic potential and apparent expression of tyrosinase activities. Am. J. Med. Sci. *308*, 322–330.

Zhao, H., Boissy, Y., Abdel-Malek, Z., King, R.A., Nordlund, J.J., and Boissy, R.E. (1994). On the analysis of the pathophysiology of Chediak-Higashi syndrome: defects expressed by cultured melanocytes. Lab. Invest. *71*, 25–34.

Zhen, L., Jiang, S., Feng, L., Bright, N.A., Peden, A.A., Seymour, A.B., Novak, E.K., Elliott, R., Gorin, M.B., Robinson, M.S., and Swank, R.T. (1999). Abnormal expression and subcellular distribution of subunit proteins of the AP-3 adaptor complex lead to platelet storage pool deficiency in the pearl mouse. Blood *94*, 146–155.

Zhou, B.-K., Boissy, R.E., Pifko-Hirst, S., Moran, D.J., and Orlow, S.J. (1993). Lysosome-associated membrane protein-1 (LAMP-1) is the melanocyte vesicular membrane glycoprotein, Band II. J. Invest. Dermatol. *100*, 110–114.